Press Releases

07.21.2023

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility

07.19.2023

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate

06.28.2023

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

06.27.2023

FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec

06.26.2023

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus

06.23.2023

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

06.22.2023

Pfizer Declares Third-Quarter 2023 Dividend

06.20.2023

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

06.20.2023

Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts

06.06.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

06.01.2023

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

05.31.2023

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults